MX2019002698A - Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb. - Google Patents

Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb.

Info

Publication number
MX2019002698A
MX2019002698A MX2019002698A MX2019002698A MX2019002698A MX 2019002698 A MX2019002698 A MX 2019002698A MX 2019002698 A MX2019002698 A MX 2019002698A MX 2019002698 A MX2019002698 A MX 2019002698A MX 2019002698 A MX2019002698 A MX 2019002698A
Authority
MX
Mexico
Prior art keywords
worsening
progression
mitigate
prevent
ameliorating
Prior art date
Application number
MX2019002698A
Other languages
English (en)
Spanish (es)
Inventor
Paul Averback
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of MX2019002698A publication Critical patent/MX2019002698A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2019002698A 2016-09-07 2017-08-29 Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb. MX2019002698A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/258,786 US10532081B2 (en) 2016-09-07 2016-09-07 Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
PCT/IB2017/055187 WO2018047036A1 (en) 2016-09-07 2017-08-29 Method of ameliorating or preventing the worsening or the progression of symptoms of bph

Publications (1)

Publication Number Publication Date
MX2019002698A true MX2019002698A (es) 2020-07-22

Family

ID=59829424

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002698A MX2019002698A (es) 2016-09-07 2017-08-29 Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb.

Country Status (12)

Country Link
US (1) US10532081B2 (cg-RX-API-DMAC7.html)
EP (2) EP3509620A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019531278A (cg-RX-API-DMAC7.html)
KR (1) KR102623470B1 (cg-RX-API-DMAC7.html)
CN (1) CN109890401A (cg-RX-API-DMAC7.html)
AU (1) AU2017325033B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019004532A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036089A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019002698A (cg-RX-API-DMAC7.html)
RU (1) RU2744691C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018047036A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201901449B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835538B2 (en) * 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US20200360466A1 (en) * 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11231421B2 (en) * 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423507A (en) 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE2817157A1 (de) 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4457489A (en) 1981-07-13 1984-07-03 Gilmore Samuel E Subsea fluid conduit connections for remote controlled valves
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
EP0378924B1 (en) 1988-12-21 1996-11-13 The General Hospital Corporation Detection of neurological disease or dysfunction
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
JPH06256387A (ja) 1991-06-14 1994-09-13 Suetsuna Yoko 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤
KR100392244B1 (ko) 1993-04-20 2003-11-28 더 제너럴 호스피탈 코포레이션 신경사단백질유전자발현및알쯔하이머병의검출
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
JPH11506722A (ja) 1995-06-07 1999-06-15 ベイラー・カレッジ・オブ・メディスン 細胞に核酸を送達するための核酸運搬体
BR9711795A (pt) 1996-03-26 2000-06-06 Razvant T Radulescu Peptìdeos tendo propriedades antiproliferativas
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
AU749348B2 (en) 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
AU9655698A (en) 1997-10-10 1999-05-03 Astra Aktiebolag Synthetic genes with immunomodulatory effects
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
EP1135494A2 (en) 1998-12-11 2001-09-26 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
AU3517000A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 50 human secreted proteins
JP2002543764A (ja) 1999-03-19 2002-12-24 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 46個のヒト分泌タンパク質
JP2002539842A (ja) 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 45個のヒト分泌タンパク質
EP1171462A2 (en) 1999-03-26 2002-01-16 Human Genome Sciences, Inc. 49 human secreted proteins
EP1220947A2 (en) 1999-03-26 2002-07-10 Human Genome Sciences, Inc. 50 human secreted proteins
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽-人神经元线蛋白17和编码这种多肽的多核苷酸
WO2002000718A2 (en) 2000-06-26 2002-01-03 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
US7259232B1 (en) 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
CA2325666A1 (fr) 2000-12-01 2002-06-01 Institut Pasteur Peptides immunogeniques mutes derives de r9m, polynucleotides les codants et leurs usages therapeutiques
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
DE60222745T2 (de) 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
JP2004529179A (ja) 2001-05-16 2004-09-24 ナイモックス コーポレーション 神経線維タンパク質のセグメントを使用する細胞死の予防法
BR0209990A (pt) 2001-05-25 2004-06-29 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE60217507T2 (de) 2001-07-19 2007-11-15 Nymox Corp., Saint-Laurent Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2005113720A2 (en) 2004-05-19 2005-12-01 Auburn University A strategy for designing patient-specific anti-cancer drugs
PL1994152T3 (pl) * 2006-02-28 2013-05-31 Nymox Corp Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek
EA200801942A1 (ru) 2006-03-10 2009-02-27 Наймокс Корпорейшн Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
US9243035B2 (en) 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US20160215031A1 (en) 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention

Also Published As

Publication number Publication date
KR20190050813A (ko) 2019-05-13
AU2017325033A1 (en) 2019-04-11
CA3036089A1 (en) 2018-03-15
KR102623470B1 (ko) 2024-01-09
RU2019110137A3 (cg-RX-API-DMAC7.html) 2020-12-07
EP3509620A1 (en) 2019-07-17
US20180064785A1 (en) 2018-03-08
AU2017325033B2 (en) 2024-11-14
EP4275688A3 (en) 2024-01-17
US10532081B2 (en) 2020-01-14
RU2744691C2 (ru) 2021-03-15
EP4275688A2 (en) 2023-11-15
RU2019110137A (ru) 2020-10-08
NZ751862A (en) 2025-11-28
JP2019531278A (ja) 2019-10-31
ZA201901449B (en) 2020-11-25
WO2018047036A1 (en) 2018-03-15
JP2023036673A (ja) 2023-03-14
CN109890401A (zh) 2019-06-14
BR112019004532A2 (pt) 2019-06-25

Similar Documents

Publication Publication Date Title
EP4275688A3 (en) Method of ameliorating or preventing the worsening or the progression of symptoms of bph
MX380201B (es) Péptido de la cadena neural para prevenir o reducir el avance de cáncer de próstata.
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
MX2017016106A (es) Composiciones de combinacion para tratar trastornos que requieren de la remocion o destruccion de proliferaciones celulares no deseadas.
MX391695B (es) Péptido derivado de una proteína de hebra neural para uso en el tratamiento de desordenes que requieren la destrucción o retiro de células
MX2023009631A (es) Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi.
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
MX2015003229A (es) Composiciones que comprenden mezclas de alcanos semifluorados.
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
MX2015012783A (es) Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13).
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
MX2022001133A (es) Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
JOP20200004A1 (ar) تركيبات طويلة المفعول
AR109799A1 (es) Composición para el tratamiento del cabello
AR110404A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l
MX2019010394A (es) Composiciones y metodos para mejorar la funcion sexual.
BR112015021480A2 (pt) soluções de hidromorfona intratecais tendo estabi-lidade melhorada
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MX2021012824A (es) Métodos para tratar el prurito.
MX2017009929A (es) Composiciones y métodos para metabolismo muscular mejorado.
MX2021002761A (es) Metodos para tratar la pancreatitis.
MX2020007162A (es) Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina.